Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency

Supportive Care in Cancer

Volumn 23, Issue 6, 2015, Pages 1657-1662

  Watkins, Karen R ^a   Rogers, Jane E ^a   Atkinson, Bradley ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone metastases; Denosumab; Hypocalcemia; Renal insufficiency

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; MONOCLONAL ANTIBODY;

AGED; BONE NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDY; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENOSUMAB; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84939978254     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2521-8     Document Type: Article

References (20)

1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
2. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19(1):80
3. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420
4. Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692
5. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132
6. Fizazi K, Carducci M, Smith M, Damião R, Brown J et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813
7. Pamidronate (Aredia®). East Hanover, New Jersey: Novartis Pharmaceuticals. 2012
8. Zoledronic acid (Zometa®). East Hanover, New Jersey: Novartis Pharmaceuticals. 2012
9. Denosumab (Xgeva®). Thousand Oaks, California: Amgen. 2013
10. Block G, Bone HG, Fang L, Lee E, Padhi D (2012) A single dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27(7):1471–1479
11. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829–1835
12. Denosumab (Prolia®). Thousand Oaks, California: Amgen. 2014
13. Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31(4):756.e1–756.e2
14. Govaerts E, Vansteenkiste J (2013) Use of denosumab in a patient with non-small-cell lung cancer and severe renal function impairment. J Thorac Oncol 8(6):e52–e53
15. Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S (2014) Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol 2014:565393. doi:10.1155/2014/565393
16. Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M et al (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36(10):1622–1626
17. Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N et al (2014) The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer 22(7):1765–1771
18. Lee JW (2010) Fluid and electrolyte disturbances in critically ill patients. Electrolyte Blood Press 8(2):72–81
19. Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y (2013) Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29(9):1067–1073
20. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9):1221–1227